129 related articles for article (PubMed ID: 12503198)
21. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Mouridsen H; Chaudri-Ross HA
Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
[TBL] [Abstract][Full Text] [Related]
22. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
23. Promising results for Arimidex and Femara.
Expert Rev Anticancer Ther; 2001 Dec; 1(4):508-9. PubMed ID: 12113080
[No Abstract] [Full Text] [Related]
24. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Baum M
Eur J Cancer; 2005 Aug; 41(12):1667-77. PubMed ID: 16046117
[TBL] [Abstract][Full Text] [Related]
25. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
26. New developments in the treatment of postmenopausal breast cancer.
Howell A
Trends Endocrinol Metab; 2005 Nov; 16(9):420-8. PubMed ID: 16213745
[TBL] [Abstract][Full Text] [Related]
27. Future directions in endocrine treatment of advanced breast cancer.
Bland KI
Ann Surg Oncol; 1999 Dec; 6(8 Suppl):14S-16S. PubMed ID: 10619455
[No Abstract] [Full Text] [Related]
28. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Buzdar AU
Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
[TBL] [Abstract][Full Text] [Related]
29. [Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition].
Internist (Berl); 1997 Mar; 38(3 Suppl Selektive):1-16. PubMed ID: 9541667
[No Abstract] [Full Text] [Related]
30. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
31. New breast cancer drug.
Brink S
US News World Rep; 2001 Dec; 131(26):52. PubMed ID: 11793594
[No Abstract] [Full Text] [Related]
32. [The ATAC study on adjuvants in breast cancer].
Bravi S
Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
[No Abstract] [Full Text] [Related]
33. Letrozole in breast cancer.
Shahab N
N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
[No Abstract] [Full Text] [Related]
34. Aromatase inhibitors continue their ATAC on tamoxifen.
Nicholls H
Trends Mol Med; 2002; 8(4 Suppl):S12-3. PubMed ID: 11927281
[No Abstract] [Full Text] [Related]
35. Stick with tried-and-true breast cancer treatment.
Health News; 2002 Jul; 8(7):5. PubMed ID: 12132502
[No Abstract] [Full Text] [Related]
36. New options in the prevention and treatment of breast carcinoma.
Galleshaw J
J Med Assoc Ga; 2003; 92(1):19-22. PubMed ID: 12743901
[No Abstract] [Full Text] [Related]
37. Superior efficacy of letrozole versus tamoxifen as first-line therapy.
Buzdar AU
J Clin Oncol; 2002 Feb; 20(3):876-8. PubMed ID: 11821477
[No Abstract] [Full Text] [Related]
38. The endocrine management of postmenopausal women with early breast cancer.
Baum M
Breast Cancer; 2004; 11(1):15-9. PubMed ID: 14718786
[No Abstract] [Full Text] [Related]
39. Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Ravdin P
Lancet; 2002 Jun; 359(9324):2126-7. PubMed ID: 12090973
[No Abstract] [Full Text] [Related]
40. ERBB2 status and outcome of endocrine treatment.
Miller WR
Lancet Oncol; 2008 Jan; 9(1):4-5. PubMed ID: 18177812
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
